Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT05223361

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05223361
Other papers using this trial's data
  • Comparison of six percent hydroxyethyl starch 130/0.4 and ringer's lactate as priming solutions in patients undergoing isolated open heart valve surgery: A double-blind randomized controlled trial Perfusion, 2025-01 DOI, PubMed 38105566

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Iran (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05223361. Randomized; triple masking; primary purpose prevention. Start 2016-04 (actual); primary completion 2021-04-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery
Condition
Heart Valve Diseases
Intervention (Drug)
Six percent hydroxy ethyl starch 130/0.4
Intervention (Drug)
Ringer lactate
Lead sponsor
Rajaie Cardiovascular Medical and Research Center (class: other)
Collaborator
Heart Valve Disease Research Center (class: not stated)

Record details

Record id
cardio:ct-nct05223361
Content hash
e41addd37914c294037cacd61f8eb3eecfc3d479f230418d9f104e03eeae0c44